Purpose, strategy and culture

Infectious diseases

There’s a huge need for innovation to tackle chronic infections, seasonal infections, common childhood diseases, rare but devastating conditions (meningitis) and a range of bacterial infections made more challenging by antimicrobial resistance (AMR); as well as diseases which predominately impact lower-income countries like malaria and TB.

Our infectious diseases portfolio is the broadest in the industry and, including HIV, accounts for two thirds of our pipeline.

HIV

Our goal is to minimise the impact of HIV on people’s lives through treatment, prevention and ultimately cure.

We are a world leader in next-generation HIV treatment and prevention, through ViiV Healthcare, the world’s only specialist HIV pharmaceutical company, which we majority own. We pioneered the first HIV treatments in the 1980s and we are leading the way in changing the landscape for people living with HIV today.

Respiratory/ immunology

We’re unlocking the science of the immune system to develop medicines for immune-mediated conditions including lupus, eosinophilic-driven diseases such as severe eosinophilic asthma, COPD and other inflammatory diseases.

Our innovative medicines help millions of people with immune and respiratory conditions.

Oncology

Our approach in oncology is to prioritise the development of novel medicines to treat blood and women’s cancers and to explore other potential breakthroughs in immuno-oncology.

We have 11 investigational medicines in our oncology pipeline that have the potential to make a meaningful difference for patients with cancer, and we’re growing our pipeline through targeted business development.